» Articles » PMID: 37175092

Pulsatilla Saponins Inhibit Experimental Lung Metastasis of Melanoma Via Targeting STAT6-Mediated M2 Macrophages Polarization

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 May 13
PMID 37175092
Authors
Affiliations
Soon will be listed here.
Abstract

(PS) extracts from Pulsatilla chinensis (Bge.) Regel, are a commonly used traditional Chinese medicine. In the previous study, we found displayed anti-tumor activity without side effects such as bone marrow suppression. However, the mechanism of the anti-tumor effect was not illustrated well. Since M2-like tumor-associated macrophages (TAMs) that required activation of the signal transducer and activator of transcription 6 (STAT6) for polarization are the important immune cells in the tumor microenvironment and play a key role in tumor progress and metastasis, this study aimed to confirm whether could inhibit the development and metastasis of tumors by inhibiting the polarization of M2 macrophages. We investigated the relevance of M2 macrophage polarization and the anti-tumor effects of in vitro and in vivo. In vitro, could decrease the mRNA level of M2 marker genes Arg1, Fizz1, Ym1, and CD206, and the down-regulation effect of phosphorylated STAT6 induced by IL-4; moreover, the conditioned medium (CM) from bone marrow-derived macrophages (BMDM) treated with could inhibit the proliferation and migration of B16-F0 cells. In vivo, could reduce the number of lung metastasis loci, down-regulate the expression of M2 marker genes, and suppress the expression of phosphorylated STAT6 in tumor tissues. Furthermore, we used AS1517499 (AS), a STAT6 inhibitor, to verify the role of PS on M2 macrophage polarization both in vitro and in vivo. We found that failed to further inhibit STAT6 activation; the mRNA level of Arg1, Fizz1, Ym1, and CD206; and the proliferation and migration of B16-F0 cells after AS1517499 intervention in vitro. Similar results were obtained in vivo. These results illustrated that could effectively suppress tumor progress by inhibiting the polarization of M2 macrophages via the STAT6 signaling pathway; this revealed a novel mechanism for its anti-tumor activity.

Citing Articles

Inhibition of programmed cell death by melanoma cell subpopulations reveals mechanisms of melanoma metastasis and potential therapeutic targets.

An Y, Zhao F, Jia H, Meng S, Zhang Z, Li S Discov Oncol. 2025; 16(1):62.

PMID: 39832036 PMC: 11747064. DOI: 10.1007/s12672-025-01789-9.


An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls.

Salmaninejad A, Layeghi S, Falakian Z, Golestani S, Kobravi S, Talebi S Clin Exp Med. 2024; 24(1):156.

PMID: 39003350 PMC: 11246281. DOI: 10.1007/s10238-024-01417-w.


Anemoside B4 attenuates abdominal aortic aneurysm by limiting smooth muscle cell transdifferentiation and its mediated inflammation.

Chu S, Shan D, He L, Yang S, Feng Y, Zhang Y Front Immunol. 2024; 15:1412022.

PMID: 38881898 PMC: 11176519. DOI: 10.3389/fimmu.2024.1412022.

References
1.
Rhee I . Diverse macrophages polarization in tumor microenvironment. Arch Pharm Res. 2016; 39(11):1588-1596. DOI: 10.1007/s12272-016-0820-y. View

2.
Wang Q, Zhang H, Mei H, Ye Y, Xu H, Xiang S . MCTR1 enhances the resolution of lipopolysaccharide-induced lung injury through STAT6-mediated resident M2 alveolar macrophage polarization in mice. J Cell Mol Med. 2020; 24(17):9646-9657. PMC: 7520340. DOI: 10.1111/jcmm.15481. View

3.
Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

4.
Gao P, Wang L, Liu J, Dong F, Song W, Liao L . Dihydroartemisinin inhibits endothelial cell tube formation by suppression of the STAT3 signaling pathway. Life Sci. 2019; 242:117221. DOI: 10.1016/j.lfs.2019.117221. View

5.
Jiang L, Zhao X, Mao Y, Wang J, Zheng H, You Q . Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6. J Exp Clin Cancer Res. 2019; 38(1):465. PMC: 6852742. DOI: 10.1186/s13046-019-1428-0. View